bluebird bio, Inc. (0HOH.L)
USD 9.28
(33.91%)
USD 9.28
(33.91%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -211.91 Million USD | 20.51% |
| 2022 | -266.57 Million USD | 52.62% |
| 2021 | -562.63 Million USD | 9.06% |
| 2020 | -618.69 Million USD | 21.65% |
| 2019 | -789.6 Million USD | -42.11% |
| 2018 | -555.62 Million USD | -65.54% |
| 2017 | -335.64 Million USD | -27.38% |
| 2016 | -263.5 Million USD | -57.99% |
| 2015 | -166.78 Million USD | -242.41% |
| 2014 | -48.7 Million USD | -92.37% |
| 2013 | -25.32 Million USD | -6.98% |
| 2012 | -23.67 Million USD | -51.75% |
| 2011 | -15.59 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -69.8 Million USD | 21.14% |
| 2024 Q2 | -81.39 Million USD | -16.6% |
| 2023 Q3 | -71.73 Million USD | 1.61% |
| 2023 Q2 | -72.9 Million USD | -314.16% |
| 2023 Q1 | 34.04 Million USD | 5.62% |
| 2023 Q4 | -88.51 Million USD | -23.4% |
| 2023 FY | -211.91 Million USD | 20.51% |
| 2022 Q3 | -76.52 Million USD | 17.61% |
| 2022 FY | -266.57 Million USD | 52.62% |
| 2022 Q2 | -92.87 Million USD | 25.07% |
| 2022 Q1 | -123.95 Million USD | 20.05% |
| 2022 Q4 | 32.23 Million USD | 142.12% |
| 2021 Q3 | -216.81 Million USD | 10.3% |
| 2021 Q4 | -155.05 Million USD | 28.49% |
| 2021 FY | -562.63 Million USD | 9.06% |
| 2021 Q2 | -241.7 Million USD | -17.44% |
| 2021 Q1 | -205.8 Million USD | -2.97% |
| 2020 Q3 | -194.74 Million USD | -807.27% |
| 2020 Q1 | -202.61 Million USD | 9.28% |
| 2020 Q2 | -21.46 Million USD | 89.41% |
| 2020 FY | -618.69 Million USD | 21.65% |
| 2020 Q4 | -199.87 Million USD | -2.63% |
| 2019 FY | -789.6 Million USD | -42.11% |
| 2019 Q1 | -164.44 Million USD | -10.35% |
| 2019 Q2 | -195.78 Million USD | -19.06% |
| 2019 Q4 | -223.34 Million USD | -8.4% |
| 2019 Q3 | -206.03 Million USD | -5.24% |
| 2018 FY | -555.62 Million USD | -65.54% |
| 2018 Q4 | -149.02 Million USD | -2.44% |
| 2018 Q3 | -145.48 Million USD | 0.35% |
| 2018 Q2 | -145.99 Million USD | -26.81% |
| 2018 Q1 | -115.12 Million USD | 1.79% |
| 2017 Q3 | -78.8 Million USD | -11.15% |
| 2017 FY | -335.64 Million USD | -27.38% |
| 2017 Q2 | -70.89 Million USD | -3.18% |
| 2017 Q1 | -68.71 Million USD | 3.72% |
| 2017 Q4 | -117.22 Million USD | -48.76% |
| 2016 Q2 | -58.84 Million USD | -4.57% |
| 2016 Q1 | -56.27 Million USD | -19.03% |
| 2016 Q3 | -77.02 Million USD | -30.9% |
| 2016 Q4 | -71.36 Million USD | 7.35% |
| 2016 FY | -263.5 Million USD | -57.99% |
| 2015 Q1 | -24.78 Million USD | -26.83% |
| 2015 FY | -166.78 Million USD | -242.41% |
| 2015 Q2 | -51.79 Million USD | -108.96% |
| 2015 Q3 | -42.92 Million USD | 17.13% |
| 2015 Q4 | -47.27 Million USD | -10.14% |
| 2014 FY | -48.7 Million USD | -92.37% |
| 2014 Q3 | -17.03 Million USD | -1015.99% |
| 2014 Q4 | -19.54 Million USD | -14.76% |
| 2014 Q1 | -10.6 Million USD | -31.28% |
| 2014 Q2 | -1.52 Million USD | 85.62% |
| 2013 Q2 | -4.58 Million USD | 29.97% |
| 2013 Q4 | -8.08 Million USD | -32.19% |
| 2013 FY | -25.32 Million USD | -6.98% |
| 2013 Q1 | -6.54 Million USD | 27.27% |
| 2013 Q3 | -6.11 Million USD | -33.38% |
| 2012 Q3 | -5.04 Million USD | -10.48% |
| 2012 Q2 | -4.56 Million USD | 9.96% |
| 2012 Q1 | -5.06 Million USD | 0.0% |
| 2012 Q4 | -8.99 Million USD | -78.5% |
| 2012 FY | -23.67 Million USD | -51.75% |
| 2011 FY | -15.59 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | -38.307% |
| Dynavax Technologies Corporation | -6.38 Million USD | -3216.841% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 16202.812% |
| Perrigo Company plc | -12.7 Million USD | -1568.606% |
| Illumina, Inc. | -1.16 Billion USD | 81.747% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 103.535% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 52.276% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 97.546% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 115.605% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -91.674% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 105.36% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -431.643% |
| Waters Corporation | 642.23 Million USD | 132.996% |
| Biogen Inc. | 1.16 Billion USD | 118.251% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 17.809% |
| Evolus, Inc. | -61.68 Million USD | -243.541% |
| Adicet Bio, Inc. | -142.65 Million USD | -48.546% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -78.81% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | -1.274% |
| FibroGen, Inc. | -284.23 Million USD | 25.444% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 117.09% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -375.106% |
| Homology Medicines, Inc. | -53.74 Million USD | -294.308% |
| Geron Corporation | -184.12 Million USD | -15.091% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 51.864% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | -39.799% |
| Myriad Genetics, Inc. | -112 Million USD | -89.208% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -146.712% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 55.961% |
| Zoetis Inc. | 2.34 Billion USD | 109.041% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -291.07% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 126.866% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 226.406% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 105.855% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -402.175% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 42.145% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 23.255% |
| Verastem, Inc. | -87.36 Million USD | -142.555% |
| Nektar Therapeutics | -276.05 Million USD | 23.236% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 11.422% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -139.501% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 60.462% |
| OPKO Health, Inc. | -188.86 Million USD | -12.205% |
| Exelixis, Inc. | 207.76 Million USD | 201.996% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 184.867% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 299.654% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -346.086% |
| uniQure N.V. | -308.47 Million USD | 31.304% |
| Imunon, Inc. | -19.51 Million USD | -985.899% |
| Blueprint Medicines Corporation | -506.98 Million USD | 58.201% |
| Insmed Incorporated | -749.56 Million USD | 71.729% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 175.255% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 39.812% |
| TG Therapeutics, Inc. | 12.67 Million USD | 1772.293% |
| Incyte Corporation | 597.59 Million USD | 135.461% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 72.135% |